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Introduction 
•  Multiple Myeloma is associated with bleeding disorders in 
approximately 15% of cases1
•  The underlying physiologic mechanisms remain incompletely 
understood and create significant clinical challenges when 
approaching treatment
•  The development of a heparin-like anticoagulant (HLAC) in 
plasma cell neoplasia has been described in literature and 
may be a mechanism of action to which bleeding occurs in 
patients with MM2
•  Infusions of protamine sulfate have been proposed as a 
potential therapy in this clinical setting2
Case Presentation
•  A 62 year-old male with a past medical history of 
Monoclonal Gammopathy of Undetermined Significance 
and basal cell carcinoma presented to the ED with 
complaints of non-radiating epigastric abdominal pain  
for one week
•  On admission he was found to have hypercalcemia, renal 
failure, and pancytopenia. Hematological work up revealed 
significantly elevated kappa light chains consistent with 
myeloma and a bone marrow biopsy revealing circulating 
plasma cells
•  His mental status did not improve over a 15-day hospital 
course he was transferred to our facility. On presentation 
the patient was not oriented to person place or time, was 
writhing, moaning and completely non verbal
•  Labs showed prolonged partial thromboplastin time (PTT) 
and thrombin time. Transfusions of platelets, blood and 
fresh frozen plasma were unable to control the bleeding
•  After literature review, the patient was started on 
protamine sulfate infusion resulting in significant 
improvement in his bleeding. The patient’s hospital course 
was complicated by acute liver failure and worsening renal 
failure and was transitioned to comfort measures only








Hemoglobin 5.9 8.5 7.7
Platelets 17.0 39.0 16.0
aPTT 42.4 32.5 52.6
PT 14.7 16.6 17.2
INR 1.2 1.4 1.5
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Discussion
•  Secretion of HLAC in Plasma Cell Neoplasia has been 
described in case reports but affirmative research on  
the topic remains sparse 
•  Literature suggests that HLAC may be paraproteins 
produced within myeloma while other studies have 
suggested these proteins that are similar to heparin 
sulfate may be responsible by binding antithrombin  
and leading to activation of the heparin binding site2,3,4
•  Regardless of the mechanism, prior cases have 
demonstrated that administration of 10, 50, 100, and  
200 mg/mL of protamine sulfate in patients with  
myeloma improved thrombin time from >600 seconds  
to 187 seconds, 76 seconds, 22 seconds, and  
21 seconds respectively3
•  In the present case, once the patient was started on 
protamine sulfate, his bleeding significantly improved and 
his PTT normalized. Once off the infusion, his PTT and 
thrombin time both became elevated again
